Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credit: iStock
With one in six laboratory-confirmed bacterial infections worldwide already resistant to antibiotics, drug-resistant infections could contribute to more than 39 million deaths by 2050 if current trends persist, according to the World Health Organization (WHO).
Speaking at the virtual 6th Annual Global Media Forum on AMR, WHO officials warned that countries are not doing enough to tackle antimicrobial resistance (AMR), despite growing commitments. They also presented findings from the latest joint survey by WHO, the United Nations Environment Programme, the World Organisation for Animal Health and the Food and Agriculture Organization.
Although more countries have adopted national action plans to combat AMR, most have failed to translate these commitments into funded and implemented programmes. As a result, the world remains off track to meet key 2030 targets.
Of the 183 countries surveyed, 173 reported having a national action plan, up from 79 in 2017. However, only 42 said their plans were financed and implemented.
Also read: Over One In Four Americans Lied To Get Antibiotics For Children: Why It Can Be Dangerous
Antimicrobial resistance occurs when bacteria, viruses, fungi and parasites evolve and no longer respond to medicines designed to treat them. This makes infections harder to treat and increases the risk of disease spread, severe illness and death.
Antibiotic resistance is a form of AMR that specifically involves bacteria becoming resistant to antibiotics. Misuse and overuse of these medicines accelerate the problem.
At the 2024 United Nations General Assembly, countries agreed on a series of targets to tackle AMR by 2030. However, experts warn that the growing threat could undermine decades of medical progress.
"Procedures we now take for granted become far riskier when antibiotics and antimicrobials no longer work," Jean-Pierre Nyemazi, acting director of WHO's AMR department, said. The development of new antibiotics is also failing to keep pace with the spread of resistance, he added, Reuters reported.
"Unlike COVID-19, which was very visible, drug-resistant infections have been taking people's lives for years without us noticing it and raising the alarm as we should," Nyemazi said at the forum.
In 2021 alone, AMR was directly responsible for more than one million deaths and associated with approximately 4.7 million others, according to WHO figures.
The 2026 survey highlighted major gaps in infection prevention, a key measure for reducing the need for antibiotics.
The WHO reported that 128 countries now have national infection prevention and control programmes and guidelines, up from 90 in 2018. However, only 69 countries, or 38%, have implemented these programmes nationwide, well below the 2030 target of 90%.
Read More: 98 Years After Penicillin: Are We Running Out Of Effective Antibiotics?
Laboratory capacity also remains limited. While 131 countries reported having national reference laboratories capable of testing antibiotic resistance in common bacteria, only 66 could test for both bacterial and fungal resistance. Countries have agreed to ensure that 80% have these capabilities by 2030.
The WHO also released two toolkits to help countries strengthen diagnostic capacity, covering essential tests and laboratory procedures.
Surveillance has improved, with 113 countries now monitoring antibiotic use and 109 tracking antimicrobial resistance, compared with 65 and 39, respectively, in 2017.
However, only 21 countries reported integrating data on antibiotic use and resistance. The WHO said combining these datasets is essential to understand how antibiotic consumption drives resistance and to guide efforts to contain it.
Antibiotics treat bacterial infections but do not work against viral infections, which commonly cause cold- and flu-like symptoms. Unnecessary use can also expose patients to side effects and contribute to antimicrobial resistance.
As per the WHO, resistance exists across 22 different antibiotics—the common drugs used to treat everyday illnesses, such as:
When bacteria develop resistance, infections become harder to treat, increasing the risk of complications and limiting available treatment options.
(With inputs from agencies)
Credit: iStock
NASA scientists warn that the developing 2026–27 El Niño could rival or surpass the powerful 1997–98 event, which triggered severe droughts, fires and flooding worldwide.
The new findings amid climate deliberations taking place at the COP31 in Turkiye.
Using 35 years of satellite observations, researchers are comparing the current event with previous strong El Niños. The climate phenomenon, marked by warmer-than-average sea-surface temperatures in the central and eastern equatorial Pacific, can disrupt weather patterns worldwide and raise global temperatures.
The 1997–98 and 2015–16 events were among the strongest on record, bringing fires to Indonesia and the Amazon, droughts in southern Africa, and heavy rainfall in Southern California.
Also read: El Niño Could Worsen Dengue, Malaria And Heat Illness: Why WHO Declared A Health Emergency
Satellite altimetry measures changes in ocean surface height, helping scientists track heat accumulation in the Pacific. Warmer seawater expands, raising sea levels.
"What's unique about altimetry is that we have a 35-year record from nearly identical satellites flying almost the same ground track, with each mission overlapping the next," said Josh Willis, project scientist for sea level missions at NASA's Jet Propulsion Laboratory (JPL). "That lets us look back in time and compare this El Niño to what happened in 1997. And right now, this one is on track to be even bigger."
NASA's October measurements show similarities between the two events, including lower sea levels in the western Pacific, higher levels in the east and unusually warm water extending towards South America.
These patterns raise the possibility of similar weather effects, including substantial rainfall across California and the southern United States this winter.
Read More: Climate Crisis Is A Health Crisis: Just 6 Actions Could Save 1.6 Million Lives, Says WHO
NOAA's October 8 outlook estimated an 83% chance of strong to very strong El Niño conditions during the first three months of 2027.
On November 12, its Climate Prediction Center classified the event as "very strong", the highest of four intensity categories. Only three other events since 1950 have reached this level: 1982–83, 1997–98 and 2015–16.
However, El Niño's effects vary by region and do not guarantee the same weather extremes everywhere.
The World Meteorological Organization (WMO) warns that El Niño could amplify climate change-related health risks, including:
A World Food Programme (WFP) analysis published in October projected that El Niño could push 49 million additional people into acute food insecurity by the end of 2027, taking the global total from 225 million to 274 million.
At least 45 countries could experience worsening food insecurity, particularly communities dependent on rain-fed agriculture. WFP warns that the effects could persist through 2027 and into early 2028.
Credit: iStock
Air pollution is emerging as an important risk factor for lung cancer in India, with more young people and women who have never smoked being diagnosed with the disease, said Dr Abhishek Shankar, Associate Professor of Radiation Oncology at the All India Institute of Medical Sciences (AIIMS).
Speaking to HealthandMe, Dr Abhishek said nearly 50% of lung cancer cases are now unrelated to smoking, marking a shift from the earlier pattern, when more than 90% of cases were associated with smoking.
“So, now we see that nearly 50% lung cancer cases are not related to smoking, otherwise it was more than 90% related to smoking,” he said.
Also read: 91% Of Indian Studies Spanning 50 Years Link Air Pollution To Diabetes, Heart Disease And Cancer
Lung cancer has traditionally been associated with older male smokers. However, Dr Abhishek said he is seeing more younger people and women who have never smoked being diagnosed with the disease.
He believes air pollution could be contributing to this changing pattern.
“Now the air pollution is emerging as a risk factor and when we have more number of younger people and women who never smoke, never been exposed to any kind of, you know, second or third smoke is now coming with lung cancer.”
“The answer is very simple that air pollution has a lot much to do in terms of lung cancer in India,” Dr Abhishek said.
According to the World Health Organization (WHO), 99% of the global population breathes air that exceeds its guideline limits and contains high levels of pollutants. Low- and middle-income countries face the highest exposures.
The International Agency for Research on Cancer (IARC) classified outdoor air pollution as a Group 1 carcinogen in 2013, identifying lung cancer as one of the cancers associated with exposure.
Delhi's air quality has deteriorated sharply in recent weeks following Diwali. PM2.5 concentrations in several parts of the capital exceeded 66 times the WHO's recommended 24-hour guideline.
Long-term exposure to fine particulate matter is also a concern for children, as it can impair lung development and affect the maximum lung capacity they attain in adulthood. PM2.5's tiny particles can penetrate deep into the lungs.
Dr Abhishek pointed to research examining the relationship between particulate matter and cancer.
“Now, there are studies about the causal relationship between air pollution and lung cancer, particularly PM 2.5.”
He added that researchers have also investigated the association between different air pollutants and cancer.
“So, there are many cancers which have been studied in reference to different components of AQI, primarily the PM 2.5, PM 10 and I think they have been associated with cancer.”
Researchers are also investigating whether specific biomarkers can help identify people more susceptible to pollution-related lung cancer.
“At the same time, we are just talking about the PM 2.5 exposure-based biomarkers; what are the, you know, unique biomarkers that are expressed only in PM 2.5 exposure-based lung cancer, and we want to identify the susceptible lung cancer population women in those cohorts.”
Read More: Is India's Toxic Air Adding To Its Diabetes Crisis? What Experts Say
Dr Abhishek advised people to avoid going outdoors unless necessary during periods of severe pollution. However, he acknowledged that staying indoors is not always practical, particularly for those who need to commute to work.
He recommended wearing N95 masks to reduce exposure to fine particulate matter.
“N95 is useful. This is said to reduce exposure to the, you know, fine particles even.”
He also highlighted the use of indoor air purifiers, which can improve indoor air quality and make breathing easier. However, he noted that more research is needed to establish whether these measures reduce the risk of acute and chronic diseases.
Dr Abhishek is involved in two studies examining air pollution, lung cancer risk and screening in India.
The AIR CARE study will investigate how different components of PM2.5 contribute to lung cancer, how pollution interacts with other risk factors such as smoking, and whether exposure-based risk assessment and biomarkers can help identify high-risk groups.
The second, the Indian Lung Screening Trial, will involve around 10 centres across the country. It will assess lung cancer screening among people aged 50–80 with a smoking history of at least 20 pack-years.
The trial aims to generate evidence on lung cancer screening in the Indian population, building on findings from international studies. Dr Abhishek said initial trends from both studies are expected by the end of next year.
© $2026 Times Horizon Private Limited